Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: A randomized trial

JAMA

Volumn 293, Issue 18, 2005, Pages 2245-2256

  Hakonarson, Hakon ^a   Thorvaldsson, Sverrir ^a   Helgadottir, Anna ^a   Gudbjartsson, Daniel ^a   Zink, Florian ^a   Andresdottir, Margret ^a   Manolescu, Andrei ^a   Arnar, David Q ^b   Andersen, Karl ^b   Sigurdsson, Axel ^b   Thorgeirsson, Gestur ^b   Jonsson, Asgeir ^b   Agnarsson, Uggi ^b   Bjornsdottir, Halldora ^b   Gottskalksson, Gizur ^b   Einarsson, Atli ^c   Gudmundsdottir, Hrefna ^c   Adalsteinsdottir, Asdis E ^a   Gudmundsson, Kolbeinn ^a   Kristjansson, Kristleifur ^a   Hardarson, Thordur ^b   Kristinsson, Arni ^b   Topol, Eric J ^d   Gulcher, Jeffrey ^a   Kong, Augustine ^a   Gurney, Mark ^a   Thorgeirsson, Gudmundur ^b   Stefansson, Kari ^a   more..

^a DECODE GENETICS   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c ICELANDIC HEART ASSOCIATION   (Iceland)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DG 031; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; MYELOPEROXIDASE; PLACEBO; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; 2 (4 (QUINOLIN 2 YL METHOXY)PHENYL) 2 CYCLOPENTYLACETIC ACID; 2-(4-(QUINOLIN-2-YL-METHOXY)PHENYL)-2-CYCLOPENTYLACETIC ACID; 5-LIPOXYGENASE-ACTIVATING PROTEIN; CARRIER PROTEIN; EPOXIDE HYDROLASE; LEUKOTRIENE E4; LIPOXYGENASE INHIBITOR; MEMBRANE PROTEIN; PEROXIDASE; QUINOLINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; AGED; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ANTAGONISM; GENETICS; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOLOGICAL MARKERS; CARRIER PROTEINS; CORONARY ARTERIOSCLEROSIS; CROSS-OVER STUDIES; EPOXIDE HYDROLASES; FEMALE; HUMANS; LEUKOTRIENE B4; LEUKOTRIENE E4; LIPOXYGENASE INHIBITORS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUINOLINES; RISK FACTORS;

EID: 18244403498     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.18.2245     Document Type: Article

References (49)

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation. 2002;106:1602-1605.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
3. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-239.
4. 4 in inflammation. Crit Rev Immunol. 1990;10:1-12.
5. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220:568-575.
6. Dahlen B, Kumlin M, Ihre E, Zetterstrom O, Dahlen SE. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax. 1997;52:342-347.
7. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced branchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax. 1997;52:348-354.
8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
9. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 2000;35:358-362.
10. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
11. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
12. 2, platelet activating factor-acetylhydrolase. Atherosclerosis. 2002;3(suppl):57-68.
13. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet. 2003;35:131-138.
14. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119:1329-1336.
15. 4 production cooperates with eotaxin to mediate the recruitment of eosinophils during allergic pleurisy in mice. J Immunol. 2001;167:524-531.
16. McDonald TL, Weber A, Smith JW. A monoclonal antibody sandwich immunoassay for serum amyloid A(SAA) protein. J Immunol Methods. 1991;144:149-155.
17. Goulet JL, Byrum RS, Key ML, Nguyen M, Wagoner VA, Koller BH. Genetic factors determine the contribution of leukotrienes to acute inflammatory responses. J Immunol. 2000;164:4899-4907.
18. van der Vliet A, Eiserich JP, Cross CE. Nitric oxide: a pro-inflammatory mediator in lung disease? Respir Res. 2000;1:67-72.
19. Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-α type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis. 2001;184:699-706.
20. Mohamed-Ali V, Flower L, Sethi J, et al. β-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab. 2001;86:5864-5869.
21. Link AA, Kino T, Worth JA, et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol. 2000;164:436-442.
22. Yang SK, Choi MS, Kim OH, et al. The increased expression of an array of C-X-C and C-C chemokines in the colonic mucosa of patients with ulcerative colitis: regulation by corticosteroids. Am J Gastroenterol. 2002;97:126-132.
23. Andersen GN, Caidahl K, Kazzam E, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum. 2000;43:1085-1093.
24. Blum A, Hathaway L, Mincemoyer R, et al. Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy post-menopausal women. J Am Coll Cardiol. 2000;35:271-276.
25. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971-976.
26. Blum A, Schenke WH, Hathaway L, et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in post-menopausal women. Am J Cardiol. 2000;86:892-895.
27. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med. 2002;252:440-447.
28. Tsen YC, Kao GY, Chang CL, et al. Evaluation and validation of a duck IgY antibody-based immunoassay for high-sensitivity C-reactive protein: avian antibody application in clinical diagnostics. Clin Chem. 2003;49:810-813.
29. 2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002;2:17-22.
30. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications, part 2. Clin Chem. 2001;47:418-425.
31. 4 production in human mononuclear phagocytes is modulated by interleukin-4-induced 15-lipoxygenase. J Pharmacol Exp Ther. 2002;300:868-875.
32. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
33. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
34. Stratford N, Britten K, Gallagher P. Inflammatory infiltrates in human coronary atherosclerosis. Atherosclerosis. 1986;59:271-276.
35. Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease: data from the Bezafibrate Infarction Prevention (BIP) Study. J Am Coll Cardiol. 2002;39:1133-1138.
36. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonicacid, and atherosclerosis. N Engl J Med. 2004;350:29-37.
37. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120-126.
38. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003;100:1238-1243.
39. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894-2900.
40. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142.
41. Schmitt D, Shen Z, Zhang R, et al. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry. 1999;38:16904-16915.
42. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391-2394.
43. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879-891.
44. Ellsworth DL, O'Dowd SC, Salami B, et al. Intensive lifestyle modification: impact on cardiovascular disease risk factors in subjects with and without clinical cardiovascular disease. Prev Cardiol. 2004;7:168-175.
45. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
46. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. Published online March 8, 2005. Accessed April 7, 2005.
47. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multiyear follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1-6.
48. 2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol. 2003;14:347-352.
49. Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet. 2005;76:505-509.